A federal judge has dismissed an antitrust lawsuit that accused Eli Lilly and Novo Nordisk of blocking access to compounded versions of their weight-loss drugs. The ruling leaves the two companies firmly in control of the GLP-1 market, even as the broader picture around these drugs keeps shifting. Employers are reconsidering coverage, pharmacies are competing on price, and patients are sharing mixed experiences with the medications. Here is what else moved in the GLP-1 world this week.
The lawsuit came from a compounding pharmacy that argued Lilly and Novo Nordisk illegally restricted access to customized versions of their GLP-1 drugs. A federal judge sided with the drugmakers and dismissed the case, which means the two companies keep their hold on the original formulas for now. This matters because compounded versions have given some patients a lower-cost way to access similar treatment when the brand-name drugs were out of reach financially. With the lawsuit dismissed, patients looking for alternatives will likely need to keep working within the pricing that Lilly and Novo Nordisk set.
Starbucks has announced it will stop covering GLP-1 drugs for weight loss under its employee health plan. The company joins a growing number of employers who are pulling back from this benefit as the cost of covering these medications adds up across large workforces. For employees who relied on that coverage, the change means either paying out of pocket or finding another way to access the drugs. This shift reflects a broader tension employers face between offering competitive health benefits and managing rising prescription drug costs.
Amazon Pharmacy has added itself to the list of major pharmacies offering GLP-1 drugs for $50, giving patients another lower-cost option outside of employer coverage. This announcement comes as more employers cut back on GLP-1 benefits, which makes direct-to-pharmacy pricing more important for people trying to afford these medications. The $50 price point puts Amazon in line with other providers who have rolled out similar programs in recent months. For readers weighing their options, comparing these direct pharmacy programs may be worth the time, especially if workplace coverage is no longer available.
Gracie McGraw, daughter of Tim McGraw, has said that using Ozempic to manage symptoms of PCOS brought back an eating disorder she had previously worked to overcome. She is speaking publicly about this experience to warn others against treating thinness as a goal in itself. Her account adds a personal voice to a wider conversation about how GLP-1 drugs can affect people who have a history of disordered eating. Readers with a similar history may want to talk with their doctor about these risks before starting or continuing this treatment.
Recent earnings reports from Lilly and Novo Nordisk show Lilly widening its lead in the obesity drug market. Novo Nordisk, meanwhile, is working to win back market share and rebuild investor confidence in its pipeline of future treatments. This divide highlights how competitive the GLP-1 market has become, even between the two companies that dominate it. For patients and investors alike, the gap between the two companies may continue to shape pricing, availability, and future drug development in this category.
These developments show that access to GLP-1 drugs is changing on several fronts at once, even as the two leading manufacturers remain firmly in control of the underlying drugs. If you rely on employer coverage for these medications, it may be worth checking with your benefits department about any upcoming changes. If cost is a concern, comparing pharmacy pricing programs like the one Amazon Pharmacy just launched could help. And if you have a history of disordered eating, a conversation with your doctor before starting or continuing GLP-1 treatment is a reasonable step to take.
Key details
A judge dismissed the antitrust suit, so Lilly and Novo keep control of GLP-1 formulas.
Starbucks will stop covering GLP-1 drugs, joining employers cutting this costly benefit.
Amazon Pharmacy now offers GLP-1 drugs for $50, adding another affordable access option.
Gracie McGraw says Ozempic revived her eating disorder, warning against chasing thinness.
Lilly's earnings show it pulling ahead of Novo in the obesity drug market race.
Sources
1 Coverage for Weight Loss As Costs Climb — Business Insider
Goodman: I started micro-dosing GLP-1 and here’s what happened — AL.com
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk — Adweek
Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market — Reuters
How to Get GLP-1 Weight Loss Drugs for $50: List of Major Pharmacies — Newsweek
Protein coffee brand Javvy explores sale, sources say — Reuters
County passes monthly employee co-pay to cut GLP-1 costs — M Live Michigan
Tim McGraw's daughter says weight loss drug triggered eating disorder — Fox News
Novo Nordisk Stock Is Gaining Thursday: What's Going On? — Benzinga
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market — CNBC